🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re thrilled to be collaborating with IUCT-Oncopole! This is an exciting project which aims to fine tune the therapeutic indications and survival of patients with metastatic breast cancer. Watch this space! artios.com/press-release/… #cancer #PARP

We’re thrilled to be attending the European Society for Radiotherapy and Oncology Annual Meeting, over the weekend. Our own, Nan Shao, from the Radiation Biology team will be in Vienna and is looking forward to networking with industry peers. #DrugDiscovery #cancer #biotech

This week, our team will be present at the Precision Cancer Medicine for the Evolving Cancer Genome and Epigenome in Italy. They are looking forward to connecting with industry peers. Reach out if you’d like to meet the team! #DrugDiscovery #cancer #DNArepair #emergingbiotech

Congratulations Professor Sir Stephen Jackson on your knighthood for services to innovation and research. We at Artios are extremley thrilled with your knighthood! #knighthood #DNARepair

Join us at ESMO - Eur. Oncology in Madrid, October 20th-24th, to learn more about our ATR Inhibitor ART0380 Phase 1 study in advanced solid tumors. artios.com/press-release/… #ESMO #DrugDiscovery #cancer #DNARepair

Today at ESMO - Eur. Oncology, we presented positive initial Phase 1/1b clinical monotherapy data for our ATR Inhibitor ART0380 in advanced solid tumors. Check out our website to learn more about our presentation: artios.com/press-release/… #ESMO #DrugDiscovery #cancer #DNARepair

We’re thrilled to see our paper on DNA double strand break repairs (DSBR) has now been published on Oxford University Press-Nucleic Acids Research. Check out the paper: academic.oup.com/nar/advance-ar… To learn more about our findings #DrugDiscovery #cancer #DNARepair

Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer. artios.com/press-release/…

At the 2024 DNA Damage, Mutation and Cancer Conference GRC on Monday March 11, Helen Robinson, our VP of biology, will provide an update on how we target DNA damage response (#DDR) pathways for #cancerdrugdevelopment. #cancerresearch

We are thrilled and honoured to receive the Cancer Research Horizons Research Horizons - Start-Up Achievement Recognition Award. This award recognises the significant progress we’ve made in our mission to target DNA damage response (#DDR) pathways for #cancerdrugdevelopment in the past 2yrs

The Artios Pharma team will be attending the upcoming American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. Graeme Smith, Marco Ranzani and Colleen Sadin will be onsite and available for meetings. Contact us at [email protected] #AACR24

We are delighted to welcome Chris Liu of RTW Investments to our Board. His expertise will be invaluable as we advance development of our #DNAdamageresponse (#DDR) drugs.

Robert Heald will be presenting at the 35th Symposium on Medicinal Chemistry 25th April rscbmcs.org/events/mcee35/ #MedChemSymp24

We are excited to kick off the Autumn conference season this month! If you attend any of these conferences and would like to learn more about our work developing DDR drugs that can impact patients with hard-to-treat solid tumors, please contact us. #Biotech #ESMO2024 #WMIF2024

Our CEO, @Niall Martin, will speak on a panel with industry leaders in the oncology space at the 10th Annual #WMIF2024 Conference. Join the conversation to explore new advances in oncology, and if you're attending, reach out to learn more about our work developing DDR therapies.

We are launching a new “Behind the Science” series that explores the science behind Artios' approach! Our first post dives into targeting DNA Damage Response (DDR) pathways to selectively kill cancer cells. Read it here : tinyurl.com/4kue9vu2 #DDRTherapies

Excited for October as we will be attending the 36th EORTC-NCI-AACR Symposium to connect with industry leaders and peers and discuss our Polθ program targeting hard-to-treat cancers. Also planning to attend this conference? Let’s connect! #ENASYMP24 #Biotech

🧬 For this month’s Behind the Science we are diving into our Polθ program, ART6043. ART6043 is a potentially first-in-class oral, potent, and highly selective reversible inhibitor targeting the Polθ polymerase domain. Want to learn more? Read here: artios.com/pipeline/#pol

November has arrived, and we're excited to engage with the scientific and investor communities at several key events. Our leadership team will present and discuss Artios' pioneering DDR therapies for solid tumors. Reach out if you want to connect!

Traditional cancer therapies can damage healthy cells and face resistance. Artios leverages the full range of DDR mechanisms for targeted, precise therapies that change the cancer treatment space. Learn more here: artios.com/science/#dcoder #Oncology #DDR #CancerResearch